After Hours 28 Jan 2026: 4506.T Sumitomo Pharma JPX JPY 2349.50: 34.42% upside
The 4506.T stock opened after hours at JPY 2349.50, up JPY 18.50 or 0.79%, as investors position ahead of Sumitomo Pharma’s earnings due 30 Jan 2026. The company posts a low price-to-earnings ratio of 6.03 and EPS of 389.46, while market cap sits near JPY 933,432,027,976.00. Volume in the session reached 9,964,300.00 shares, close to the average. This earnings spotlight explains what to watch in guidance, trial updates, and how the Healthcare sector backdrop may shape the next move for 4506.T stock.
4506.T stock: earnings snapshot and near-term drivers
Sumitomo Pharma (4506.T) reports results on 30 Jan 2026, with investors focused on sales, operating margin, and pipeline progress. Key drivers include global drug launches, partnership revenue from Roivant and others, and R&D expense trends. Management guidance and any update on late-stage assets will affect revenue and EPS trajectory for FY 2026. Watch short-term catalysts and any revision to guidance that could shift market expectations for 4506.T stock.
Financials and valuation: metrics that matter for 4506.T stock
At PE 6.03 and EPS 389.46, Sumitomo Pharma trades below the Healthcare sector average PE of 23.45, signaling valuation support if fundamentals hold. The company shows strong profitability: net margin 34.75% and ROE 79.61%. Debt to equity is 0.99, and current ratio is 1.36, which points to moderate leverage and liquidity. These ratios frame how the earnings print could re-rate 4506.T stock relative to peers.
Meyka AI grade and analyst view on 4506.T stock
Meyka AI rates 4506.T with a score of 69.78 out of 100 — Grade B, HOLD. This grade factors in S&P 500 and sector comparisons, financial growth, key metrics, analyst consensus, and forecasts. The rating highlights strong profitability and a low PE, offset by working capital cycles and mixed cash flow growth. The grade is informational only and not investment advice.
Technicals and market activity ahead of the report for 4506.T stock
Technicals show an overbought RSI of 75.50 and MACD histogram at 57.06, which can presage short-term volatility. Day range was JPY 2288.00–2424.00 with a 50-day average of JPY 2457.88 and 200-day average JPY 1552.06. On balance volume remains positive, but the MFI at 92.02 signals heavy buying. Traders should expect intraday swings for 4506.T stock around the earnings release.
Sector context and investor implications for 4506.T stock
Healthcare peers trade at higher multiples, with sector PE near 23.45, so Sumitomo Pharma’s low PE suggests value if growth resumes. The sector’s recent performance shows modest gains year-to-date, and drugmakers with clear pipeline catalysts have outperformed. For investors, the choice is between value exposure to drug margins and event risk from guidance or trial news that could move 4506.T stock.
Risks, opportunities, and what to watch in the earnings report for 4506.T stock
Risks include disappointing guidance, slower product uptake, or higher R&D spend that weighs on free cash flow. Opportunities are positive trial readouts, stronger licensing revenue, or upgraded guidance driving re-rating. Specifically look for commentary on sales by geography, margin drivers, and cash conversion. Market context from regional trading could amplify the reaction source and broader Asia flows may matter too source.
Final Thoughts
Key takeaways for 4506.T stock: Sumitomo Pharma trades at JPY 2349.50 with a low PE of 6.03, strong EPS of 389.46, and deep profitability metrics. Meyka AI’s forecast model projects a monthly price of JPY 3157.81, implying a 34.42% upside versus the current price JPY 2349.50; forecasts are model-based projections and not guarantees. We set illustrative price targets: Conservative JPY 2600.00 (+10.66%), Base JPY 3000.00 (+27.70%), and Bull JPY 3500.00 (+48.96%). Watch earnings guidance, pipeline updates, and cash flow notes on 30 Jan 2026; strong operational beats could re-rate the stock, while weak guidance could compress multiples toward sector norms. Meyka AI provides this as AI-powered market analysis to help frame the earnings event, not as investment advice.
FAQs
When does Sumitomo Pharma report earnings and why does it matter for 4506.T stock?
Sumitomo Pharma reports on 30 Jan 2026. The print matters because guidance, margin commentary, and pipeline updates can move 4506.T stock significantly, given the company’s low PE and high earnings yield.
What are the main valuation metrics for 4506.T stock to watch?
Key metrics are PE 6.03, EPS 389.46, market cap JPY 933,432,027,976.00, and net margin 34.75%. Watch free cash flow and debt ratios for sustainability.
How does the healthcare sector view affect 4506.T stock?
Healthcare trades at PE 23.45 on average. If Sumitomo Pharma shows renewed growth, 4506.T stock could re-rate toward sector multiples; weak growth keeps it at a discount.
What upside does Meyka AI forecast for 4506.T stock?
Meyka AI’s model projects a monthly price of JPY 3157.81, implying 34.42% upside from JPY 2349.50. Forecasts are projections, not guarantees.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.
